Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2011

View Archived Issues

New vaccine shows promise in several models of infection

Phase III data support safety of dextromethorphan hydrobromide/quinidine sulfate in MS

Trial confirms earlier results with PET imaging agent florbetaben (18F)

Ampio Pharmaceuticals presents data from first-in-human Ampion trial

New TRPV4 channel antagonists disclosed

Adventrx and FDA agree on pivotal ANX-514 trial

Anthera Pharmaceuticals completes enrollment in PEARL-SC trial

MOC-carboetomidate induces hypnosis without adrenocortical suppression

Subcutaneous and intravenous secukinumab formulations evaluated in plaque psoriasis

Novel vasopressin V1A receptor antagonists designed by Roche

New Wnt signaling inhibitors discovered in Germany

TopoTarget patents new nicotinamide phosphoribosyltransferase inhibitors

Marina Biotech presents novel nucleic acid complexes

Intellect Neurosciences initiates development of new platform technology for proteinopathies

KemPharm to develop first-in-class oral hydromorphone prodrug

New Toll-like receptor 2 agonists prepared by IRM

Researchers at Abbott claim novel inhibitors of Bcl-2

Alexza Pharmaceuticals submits MAA for Adasuve

Marshall Edwards and Ausio Pharmaceuticals enter licensing agreement for AUS-131

Neuralstem completes phase Ia trial of NSI-189 in major depressive disorder

MHRA clears MediGene's clinical formulation study of RhuDex

Gilead files NDA for antiretroviral Quad regimen

European indication of Prevenar 13 extended

European Commission extends Alimta approval

FDA clears Ventana's companion algorithm for image analysis in HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.